Patents by Inventor Nicholas Newcombe

Nicholas Newcombe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel fused triazolones and the uses thereof
    Publication number: 20070149560
    Abstract: This invention relates to novel compounds having the structural diagram (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: March 10, 2004
    Publication date: June 28, 2007
    Applicant: AstraZeneca AB
    Inventors: Susan Ashwell, Jayachandran Ezhuthachan, Paul Lyne, Nicholas Newcombe, Martin Pass, Vibha Oza, Mei Su, Dorin Toader, Dingwei Yu, Yan Yu
  • Metalloproteinase inhibitor compounds
    Publication number: 20060287338
    Abstract: Compounds of the formula I useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.
    Type: Application
    Filed: August 24, 2006
    Publication date: December 21, 2006
    Applicant: AstraZeneca AB
    Inventors: Christophe Barlaam, Robert Dowell, Maurice Finlay, Nicholas Newcombe, Howard Tucker, David Waterson
  • 4-Imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity
    Publication number: 20060074096
    Abstract: Compounds of the formula (I): wherein R1, R2, R3, R4, R5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.
    Type: Application
    Filed: March 6, 2003
    Publication date: April 6, 2006
    Inventors: Nicholas Newcombe, Andrew Thomas
  • Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
    Publication number: 20060004033
    Abstract: Compounds of the formula (I): wherein R1, R2, R3, R4, R5, R6, p, q, and n are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.
    Type: Application
    Filed: June 29, 2005
    Publication date: January 5, 2006
    Inventors: Gloria Breault, Nicholas Newcombe, Andrew Thomas
  • Pyrimidine compounds
    Publication number: 20050256311
    Abstract: Compounds of the formula (I), wherein R1, R2, R3, R4, R5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.
    Type: Application
    Filed: March 6, 2003
    Publication date: November 17, 2005
    Inventors: Nicholas Newcombe, Andrew Thomas
  • Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity
    Publication number: 20050131000
    Abstract: Compounds of the formula (I): wherein R1, R2, R3, R4, R5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.
    Type: Application
    Filed: March 6, 2003
    Publication date: June 16, 2005
    Applicant: AstraZeneca AB
    Inventors: Nicholas Newcombe, Andrew Thomas
  • Pyrimidine compounds
    Publication number: 20050119291
    Abstract: Compounds of the formula (I) wherein R1, R2, R3, R4, R5, R6 and p are as defined within and a pharmaceutically acceptable salts and (in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.
    Type: Application
    Filed: March 6, 2003
    Publication date: June 2, 2005
    Applicant: AstraZeneca AB
    Inventors: Nicholas Newcombe, Andrew Thomas